Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo shot CagriSema shows promise for diabetes and weight loss

NCT ID NCT06323174

Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new investigational medicine called CagriSema in 189 adults with type 2 diabetes whose blood sugar was not well controlled by diet and exercise alone. Participants received either CagriSema or a placebo injection once a week for about a year. The main goal was to see if CagriSema could lower blood sugar (HbA1c) and help with weight loss compared to placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

189 people

The number who actually took part.

Started

Mar 2024

Finished

Dec 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female * Age 18 years or above at the time of signing the informed consent * Diagnosed with type 2 diabetes \>=30 days before screening * HbA1c 7.0-9.5 percent (53-80 millimoles per mole \[mmol/mol\]) (both inclusive) as determined by central laboratory at screening * Body mass index (BMI) \>=23 kilograms per square meter (kg/m\^2) at screening. BMI will be calculated in the electronic case report form (eCRF) based on height and body weight at screening Exclusion Criteria: * Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using a highly effective contraceptive method * Renal impairment with estimated Glomerular Filtration Rate less than 30 milliliter per minute per 1.73 square meter (ml/min/1.73 m\^2) as determined by central laboratory at screening * Treatment with any medication for the indication of diabetes or obesity within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed * History of use of any injectable therapy for diabetes or obesity. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed * Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 2 diabetes

Contacts and locations

Locations

  • Alliance for Multispec Res

    Newton, Kansas, 67114, United States

  • Amarillo Medical Specialists

    Amarillo, Texas, 79124, United States

  • Arcturus HC PLC Troy Med Res

    Troy, Michigan, 48098, United States

  • Azienda Ospealiero Universitaria Policlinico Umberto I

    Roma, 00161, Italy

  • Azienda Ospedaliera Papa Giovanni XXIII

    Bergamo, 24127, Italy

  • Belinus Bt.

    Debrecen, Hajdú-Bihar, 4025, Hungary

  • Borbánya Praxis E.Ü. Kft.

    Nyíregyháza, Szabolcs-Szatmar Varmegye, 4405, Hungary

  • Brigham & Women's Hospital

    Boston, Massachusetts, 02115, United States

  • CHC Zvezdara, Clinical department for endocrinology

    Belgrade, 11000, Serbia

  • Centrum Medyczne Medyk Sp. z o.o.

    Rzeszów, Podkarpackie Voivodeship, 35-055, Poland

  • Centrum Terapii Wspolczesnej J.M. Jasnorzewska S.K.A.

    Lodz, 90-338, Poland

  • Chinese People's Liberation Army General Hospital-Endocrinology

    Beijing, Beijing Municipality, 100853, China

  • Clinical Hospital Center Bezanijska Kosa

    Belgrade, 11080, Serbia

  • Clinical Hospital Centre Zemun

    Belgrade, 11080, Serbia

  • Consano Clinical Research, LLC

    Shavano Park, Texas, 78231, United States

  • Elligo Clin Res Centre

    Austin, Texas, 78704, United States

  • Encore Medical Research LLC

    Hollywood, Florida, 33024, United States

  • Encore Medical Research of Weston

    Weston, Florida, 33331, United States

  • Headlands Research Brownsville

    Brownsville, Texas, 78526, United States

  • Headlands Research Orlando

    Orlando, Florida, 32819, United States

  • Holston Medical Group

    Kingsport, Tennessee, 37660, United States

  • IRCCS Ospedale San Raffaele Milano

    Milan, 20132, Italy

  • Jinan Central Hospital

    Ji'Nan, Shandong, 250000, China

  • Jinan Central Hospital

    Jinan, Shandong, 250000, China

  • King Abdulaziz Hospital-Al Ahsa-National Guard

    Al Ahsa, 36428, Saudi Arabia

  • King Fahad Medical City

    Riyadh, 11525, Saudi Arabia

  • King Khaled University Hospital,King Saud Univ. Med. City

    Riyadh, 12372, Saudi Arabia

  • King Salman Bin Abdulaziz Hospital

    Riyadh, 12769, Saudi Arabia

  • NBR Polska Tomasz Klodawski

    Warsaw, 00-710, Poland

  • Nat Res Inst Huntington Park

    Huntington Park, California, 90255, United States

  • National Guard Hospital - Jeddah

    Jeddah, 21423, Saudi Arabia

  • Northeast Clinical Research of San Antonio

    San Antonio, Texas, 78233, United States

  • Osteo-Medic s.c. A. Racewicz, J. Supronik

    Bialystok, 15-351, Poland

  • PVN Kutató Kft.

    Budapest, 1102, Hungary

  • Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych I Administracji

    Warsaw, 02-507, Poland

  • Policlinic for diabetes

    Zaječar, 19000, Serbia

  • Policlinico Mater Domini Università di Catanzaro

    Catanzaro, 88100, Italy

  • Renew Clinic Sp. z o.o.

    Bialystok, 15-797, Poland

  • Southern California Dermatology

    Santa Ana, California, 92701, United States

  • Southgate Medical Group, LLP

    West Seneca, New York, 14224, United States

  • Sugar Lakes Family Practice PA

    Sugar Land, Texas, 77479, United States

  • Summit Research Network Oregon Inc.

    Portland, Oregon, 97210, United States

  • Szent Margit Rendelőintézet Nonprofit Kft.

    Budapest, 1032, Hungary

  • TPMG Clinical Research

    Newport News, Virginia, 23606, United States

  • The Affiliated Hospital of Jiangsu University-Endocrinology

    Zhenjiang, Jiangsu, 212001, China

  • The Second Affiliated Hospital of Nanjing Medical University-Endocrinology

    Nanjing, Jiangsu, 210011, China

  • Valley Clinical Trials, Inc.

    Northridge, California, 91325, United States

  • Valley Diab. & Endo Comp Ctr

    Weslaco, Texas, 78596, United States

  • Velocity Clinical Res-Dallas

    Dallas, Texas, 75230, United States

  • Velocity Nova Sp. z o.o.

    Zamość, 22-400, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.